cMyC®

Cardiac Specific Biomarker

Patented biomarker for cardiac injury. 

cMyC®

Cardiac Specific Biomarker

Patented biomarker for cardiac injury. 

cMyC Patents

International (PCT), European Union, UK, USA, Canada, China and Japan.

  • CMYBP-C and MLC2 as Diagnostic Marker of Cardiac Injury
  • Hybridoma Cell Lines (MY-C-CC0C2-259-1 A4) and use thereof for producing a monoclonal antibody against human cardiac myosin binding protein C (C-PROTEIN, MYBPC3, CMYBP-C OR MY-C)
  • Hybridoma Cell Lines (MY-C-CC0C2-235-3H8) and use thereof for producing a monoclonal antibody against human cardiac myosin binding protein C (C-PROTEIN, MYBPC3, CMYBP-C OR MY-C)

cMyC license rights for Lab and POC manufacturers

If you are interested in licensing the cMyC rights
for implementation on your Lab or Point of Care systems,
please contact us.

Antibodies, calibrants and samples can be made available for platform evaluation.
Contact us for more information
License
KDx Acceleration 
38 rue de Berri
75008 Paris
France
Legal

Imprint: KDx Acceleration, 38 rue de Berri, 75008 Paris, France

Legal: Disclaimer, Privacy Policy, Patents

© Copyright 2021-2024 KDx Acceleration. All rights reserved.

© Copyright 2021 KDx Acceleration. All rights reserved.